Congreso Argentino de Hipertensión Arterial 2013
XX CONGRESO ARGENTINO DE HIPERTENSION ARTERIAL
Del 18 al 20 de abril de 2013. Centro de Convenciones “Metropolitano” – Rosario.
Esta sección mostrará algunos trabajos que puedan ser útiles a nuestros facultativos por su interés práctico o teórico.
Drugs and Orthostatic Hypotension: Evidence from Literature
Por: Valeria Milazzo, Cristina Di Stefano, Serena Servo, Valentina Crudo, Chiara Fulcheri, Simona Maule y Franco Veglio. Journal of Hypertension: Open Access, J Hypertens 2012, 1:2.
Orthostatic hypotension is defined as the reduction of systolic blood pressure of at least 20 mmHg or the dropping of diastolic blood pressure of at least 10 mmHg within 3 minutes of standing compared to baseline values. It can be divided into neurogenic and non neurogenic forms. Neurogenic forms are caused by a primitive damage to autonomic nervous system, while drugs are the most common cause of non neurogenic orthostatic hypotension; they may also complicate or aggravate neurogenic forms.
Many drugs can determine orthostatic hypotension, including both cardiovascular drugs and therapies used for neurological and psychiatric disorders. This effect is furthermore enhanced by multiple pharmacological treatments. It is important for the clinician to know the potential hazard of orthostatic hypotension, in order to avoid syncope, falls, hypoperfusion symptoms, excess of mortality and loss of compliance to treatment. [publicado 15 de noviembre 2012]
Factores de riesgo del síndrome metabólico en la muerte súbita cardíaca
Por: Dr. Luis Alberto Ochoa Montes, Dr. Carlos Armando Yong Medina, Dr. Raúl Orlando Calderín Bouza, Lic. Mileidys González Lugo, Dr. Ramón Miguélez Nodarse, Dr. Ernesto Vilches Izquierdo y Dr. Henrry Díaz Londres. Rev cubana med vol.50 no.4, La Habana oct.-dic. 2011.
El 10,4 % de las muertes estudiadas acontecieron de forma súbita. En el 9,3 % de los casos se constató la presencia de síndrome metabólico. Los factores de riesgo aterogénicos documentados fueron hipertensión arterial (79,8 %), dislipidemias (24,3 %), diabetes mellitus (23,1 %) y obesidad (20,2 %). Se registró la presencia de 3 factores de síndrome metabólico en el 9,3 % de los casos.
La presencia de factores de riesgo del síndrome metabólico en víctimas de muerte súbita cardíaca, resultó frecuente, se destacaron la hipertensión arterial y las dislipidemias. [publicado: 15 de noviembre 2012]
A manera de editorial. Los trabajos y opiniones que aquí se exponen son orientadores de lo que se publica en Cuba y en el mundo sobre aspectos relevantes de la hipertensión arterial.
Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension
Por: José M. Marin, MD, Alvar Agusti, MD, Isabel Villar, PhD, Marta Forner, PhD, David Nieto, MD, Santiago J. Carrizo, MD, Ferran Barbé, MD, Eugenio Vicente, MD, Ying Wei, PhD, F. Javier Nieto, MD, PhD, Sanja Jelic, MD. JAMA. 2012;307(20):2169-2176.
Systemic hypertension is prevalent among patients with obstructive sleep apnea (OSA). Short-term studies indicate that continuous positive airway pressure (CPAP) therapy reduces blood pressure in patients with hypertension and OSA. Compared with participants without OSA, the presence of OSA was associated with increased adjusted risk of incident hypertension; however, treatment with CPAP therapy was associated with a lower risk of hypertension. [publicado 15 de noviembre 2012.]
Investigaciones expone trabajos actuales, de carácter investigativo sobre la hipertensión arterial.
Por: Katarzyna Stolarz-Skrzypek, MD, PhD; Tatiana Kuznetsova, MD, PhD; Lutgarde Thijs, MSc; Valérie Tikhonoff, MD, PhD; Jitka Seidlerová, MD, PhD; Tom Richart, MD; Yu Jin, MD; Agnieszka Olszanecka, MD, PhD; Sofia Malyutina, MD, PhD; Edoardo Casiglia, MD, PhD; Jan Filipovský, MD, PhD; Kalina Kawecka-Jaszcz, MD, PhD; Yuri Nikitin, MD, PhD; Jan A. Staessen, MD, PhD; for the European Project on Genes in Hypertension (EPOGH) Investigators. JAMA. 2011;305(17):1777-1785.
Extrapolations from observational studies and short-term intervention trials suggest that population-wide moderation of salt intake might reduce cardiovascular events. In this population-based cohort, systolic blood pressure, but not diastolic pressure, changes over time aligned with change in sodium excretion, but this association did not translate into a higher risk of hypertension or CVD complications. Lower sodium excretion was associated with higher CVD mortality. [publicado 15 de noviembre de 2012.]
Comentarios recientes